HUTCHMED (China) (HMDCF) Long-Term Investments (2014 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Long-Term Investments came in at $11.0 million in Q2 2026, up 120.4% year-over-year from $5.0 million in Q2 2025, and up 1.43% quarter-over-quarter from $10.9 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Long-Term Investments (2014 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Long-Term Investments for 13 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Long-Term Investments rose 120.4% year-over-year to $11.0 million in Q2 2026; TTM through Jun 2026 was $11.0 million, a 120.4% increase from a year earlier, with the FY2025 full-year figure at $10.9 million, changed N/A from the prior year.
- Long-Term Investments was $11.0 million for Q2 2026 at HUTCHMED (China), up from $10.9 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $83.0 million in Q2 2022 and troughed at $130000.0 in Q4 2022.
- A 5-year average of $32.6 million and a median of $11.0 million in 2026 frame the typical range for Long-Term Investments.
- Across the five-year window, Long-Term Investments slumped 99.83% in 2022 and jumped 120.4% in 2026, its largest moves.
- Over 5 years, Long-Term Investments stood at $130000.0 in 2022, then surged by 28930.77% to $37.7 million in 2023, then surged by 113.35% to $80.5 million in 2024, then slumped by 86.51% to $10.9 million in 2025, then grew by 1.43% to $11.0 million in 2026.
- The last three Long-Term Investments figures came in at $11.0 million (Q2 2026), $10.9 million (Q4 2025), and $5.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 5.79 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 9.83 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | -4.00 Mn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 1.77 Bn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 11.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.02 Mn |
| Dec 31, 2025 | 10.87 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Jun 30, 2024 | 80.52 Mn |
| Jun 30, 2023 | 37.74 Mn |
| Dec 31, 2022 | 130,000.00 |
| Jun 30, 2022 | 83.00 Mn |
| Dec 31, 2021 | 76.48 Mn |
| Jun 30, 2021 | 118.32 Mn |
| Mar 31, 2021 | 133.82 Mn |
| Dec 31, 2020 | 139.51 Mn |
| Jun 30, 2020 | 106.97 Mn |
| Dec 31, 2019 | 98.94 Mn |
| Sep 30, 2019 | 145.34 Mn |
| Jun 30, 2019 | 146.98 Mn |
| Mar 31, 2019 | 158.93 Mn |
| Dec 31, 2018 | -8.00 Mn |
| Sep 30, 2018 | 73.65 Mn |
| Jun 30, 2018 | 161.59 Mn |
| Mar 31, 2018 | 85.86 Mn |